Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YB1-v3.0
- Development stage
- Unknown
- Lead developer
- Salvectors Biotechnology
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
YB1-v3.0 is a proprietary, engineered *Salmonella typhimurium* strain designed as a tumor-targeting drug delivery platform. Developed by Shaoxing Salvectors Biotechnology, the strain is modified to selectively colonize and replicate within the hypoxic and necrotic environments characteristic of solid tumors while remaining attenuated in healthy tissues. This microbial therapy platform serves as a carrier for various therapeutic payloads, such as prodrug-converting enzymes or immunomodulators, to enhance local efficacy and minimize systemic toxicity. The lead candidate derived from this platform, YB1-X7, is an oncolytic bacterial therapy that has received Investigational New Drug (IND) clearance from both the U.S. FDA and China's NMPA for the treatment of advanced malignant solid tumors.
02
Targets
TEC (Tumor-associated vascular endothelial cell)
Beyond the preview
Go deeper on YB1-v3.0.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YB1-v3.0.